• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.

作者信息

Ferreira João Pedro, Barros António, Pitt Bertram, Montalescot Gilles, de Sa Esteban Lopez, Hamm Christian W, Flather Marcus, Verheugt Freek, Shi Harry, Leite-Moreira Adelino, Vincent John, Rossignol Patrick, Zannad Faiez

机构信息

Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, and Inserm U1116, CHRU de Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.

Cardiovascular Research and Development Unit, Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Porto, Portugal.

出版信息

Clin Res Cardiol. 2018 Dec;107(12):1192-1195. doi: 10.1007/s00392-018-1373-5. Epub 2018 Sep 27.

DOI:10.1007/s00392-018-1373-5
PMID:30264283
Abstract
摘要

相似文献

1
Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial.预测心肌梗死患者对依普利酮抗纤维化反应的胶原蛋白生物标志物生物谱：来自 REMINDER 试验的结果。
Clin Res Cardiol. 2018 Dec;107(12):1192-1195. doi: 10.1007/s00392-018-1373-5. Epub 2018 Sep 27.
2
Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.抗纤维化反应对醛固酮受体拮抗剂治疗的影响因素：来自依普利酮治疗急性心肌梗死后心力衰竭疗效和生存研究（EPHESUS）和早期依普利酮治疗急性 ST 段抬高型心肌梗死无心力衰竭患者（REMINDER）试验的研究结果。
Clin Res Cardiol. 2020 Feb;109(2):194-204. doi: 10.1007/s00392-019-01500-3. Epub 2019 Jun 27.
3
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.依普利酮对无心力衰竭的急性 ST 段抬高型心肌梗死患者细胞外心脏基质生物标志物的影响：来自随机、双盲、安慰剂对照的 REMINDER 研究的结果。
Clin Res Cardiol. 2018 Jan;107(1):49-59. doi: 10.1007/s00392-017-1157-3. Epub 2017 Aug 29.
4
The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes.醛固酮受体拮抗剂依普利酮可抑制 2 型糖尿病患者皮下脂肪组织的间质纤维化。
Diabetes. 2021 Jan;70(1):196-203. doi: 10.2337/db20-0394. Epub 2020 Oct 14.
5
Estimated Long-Term Survival With Eplerenone.依普利酮的长期生存估计。
J Am Coll Cardiol. 2019 May 14;73(18):2357-2359. doi: 10.1016/j.jacc.2019.02.043.
6
The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis.选择性盐皮质激素受体拮抗剂依普利酮可预防肝硬化失代偿。
Br J Pharmacol. 2018 Jul;175(14):2956-2967. doi: 10.1111/bph.14341. Epub 2018 Jun 7.
7
Eplerenone Improves Pulmonary Vascular Remodeling and Hypertension by Inhibition of the Mineralocorticoid Receptor in Endothelial Cells.依普利酮通过抑制内皮细胞中的盐皮质激素受体改善肺血管重塑和高血压。
Hypertension. 2021 Aug;78(2):456-465. doi: 10.1161/HYPERTENSIONAHA.120.16196. Epub 2021 May 10.
8
Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial).螺内酯对 2 型糖尿病患者肝脏脂肪和代谢的影响：一项随机、双盲、安慰剂对照试验（MIRAD 试验）。
Diabetes Obes Metab. 2019 Oct;21(10):2305-2314. doi: 10.1111/dom.13809. Epub 2019 Jul 5.
9
Authors' Response: Possible dose-dependent effect of eplerenone on intraocular pressure.作者回复：依普利酮对眼压可能存在剂量依赖性效应。
Indian J Ophthalmol. 2024 Aug 1;72(8):1227. doi: 10.4103/IJO.IJO_487_24. Epub 2024 Jul 29.
10
The role of mineralocorticoid receptor antagonists in patients with acute myocardial infarction: Is the evidence reflective of modern clinical practice?盐皮质激素受体拮抗剂在急性心肌梗死患者中的作用：现有证据是否反映现代临床实践？
Cardiovasc Revasc Med. 2018 Jun;19(4):452-456. doi: 10.1016/j.carrev.2018.04.012. Epub 2018 Apr 17.

引用本文的文献

1
Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure (REMINDER) trials.抗纤维化反应对醛固酮受体拮抗剂治疗的影响因素：来自依普利酮治疗急性心肌梗死后心力衰竭疗效和生存研究（EPHESUS）和早期依普利酮治疗急性 ST 段抬高型心肌梗死无心力衰竭患者（REMINDER）试验的研究结果。
Clin Res Cardiol. 2020 Feb;109(2):194-204. doi: 10.1007/s00392-019-01500-3. Epub 2019 Jun 27.
2
Polyhedral erythrocytes in intracoronary thrombus and their association with reperfusion in myocardial infarction.冠状动脉内血栓中的多面红细胞及其与心肌梗死后再灌注的关系。
Clin Res Cardiol. 2019 Aug;108(8):950-962. doi: 10.1007/s00392-019-01425-x. Epub 2019 Feb 1.

本文引用的文献

1
Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives.心力衰竭中心肌间质纤维化：生物学和转化视角。
J Am Coll Cardiol. 2018 Apr 17;71(15):1696-1706. doi: 10.1016/j.jacc.2018.02.021.
2
Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis.FIBROTARGETS 研究的基本原理旨在确定心肌纤维化的新型生物标志物。
ESC Heart Fail. 2018 Feb;5(1):139-148. doi: 10.1002/ehf2.12218. Epub 2017 Oct 7.
3
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study.
依普利酮对无心力衰竭的急性 ST 段抬高型心肌梗死患者细胞外心脏基质生物标志物的影响：来自随机、双盲、安慰剂对照的 REMINDER 研究的结果。
Clin Res Cardiol. 2018 Jan;107(1):49-59. doi: 10.1007/s00392-017-1157-3. Epub 2017 Aug 29.
4
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?在心力衰竭患者中定制盐皮质激素受体拮抗剂治疗：我们是否正在朝着个体化治疗的方向发展？
Eur J Heart Fail. 2017 Aug;19(8):974-986. doi: 10.1002/ejhf.814. Epub 2017 Apr 12.
5
Incidence and outcomes of early left ventricular thrombus following ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后早期左心室血栓形成的发生率和转归。
Clin Res Cardiol. 2017 Sep;106(9):695-701. doi: 10.1007/s00392-017-1111-4. Epub 2017 Apr 10.
6
Myocardial fibrosis: biomedical research from bench to bedside.心肌纤维化：从 bench 到 bedside 的生物医学研究
Eur J Heart Fail. 2017 Feb;19(2):177-191. doi: 10.1002/ejhf.696.
7
Fibroblast Senescence as a Therapeutic Target of Myocardial Fibrosis: Beyond Spironolactone?成纤维细胞衰老作为心肌纤维化的治疗靶点：螺内酯之外？
J Am Coll Cardiol. 2016 May 3;67(17):2029-31. doi: 10.1016/j.jacc.2016.02.048.
8
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial.急性心肌梗死早期醛固酮阻断：ALBATROSS 随机临床试验。
J Am Coll Cardiol. 2016 Apr 26;67(16):1917-27. doi: 10.1016/j.jacc.2016.02.033.
9
Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential.寻找具有诊断和/或治疗潜力的心肌纤维化新机制。
Eur J Heart Fail. 2015 Aug;17(8):764-71. doi: 10.1002/ejhf.312. Epub 2015 Jun 30.
10
Circulating Biomarkers of Myocardial Fibrosis: The Need for a Reappraisal.循环心肌纤维化生物标志物：重新评估的必要性。
J Am Coll Cardiol. 2015 Jun 9;65(22):2449-56. doi: 10.1016/j.jacc.2015.04.026.